Updates are available Correction dated 2024-02-05
Click to view Correction: https://doi.org/10.1186/s12943-024-01949-5
-
Authors
Champhekar, Ameya https://orcid.org/0000-0002-2758-0442
Heymans, Rachel
Saco, Justin
Turon Font, Guillem
Gonzalez, Cynthia
Gao, Anne
Pham, John
Lee, June
Maryoung, Ryan
Medina, Egmidio
Campbell, Katie M.
Karin, Daniel
Austin, David
Damioseaux, Robert
Ribas, Antoni https://orcid.org/0000-0003-3669-8458
-
Funding
Funding for this research was provided by:
Office of Extramural Research, National Institutes of Health (R35 CA197633)
- License Information
-
More Information
Article History
Received: 22 August 2023
Accepted: 25 September 2023
First Online: 6 October 2023
Change Date: 5 February 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12943-024-01949-5
Declarations
:
: A.C. and A.R. report a pending patent covering the use of ERK activators for cancer immunotherapy. K.M.C. has received consulting fees from PACT Pharma, Tango Therapeutics, Flagship Labs 81 LLC, the Rare Cancer Research Foundation, and Geneoscopy LLC, and is a shareholder in Geneoscopy LLC. G.A-R. has received honoraria from consulting with Arcus Biosciences. A.R. has received honoraria from consulting with Amgen, Bristol-Myers Squibb, Merck, Novartis, is or has been a member of the scientific advisory board and holds stock in Appia, Apricity, Arcus, Compugen, CytomX, Highlight, ImaginAb, ImmPact, Inspirna, Larkspur, Lutris, MapKure, Merus, Pluto, Synthekine and Tango, has received research funding from Agilent and from Bristol-Myers Squibb through Stand Up to Cancer (SU2C), and patent royalties from Arsenal Bio. RD has received consulting fees from Amgen, Panorama Medicine and is co-founder of Forcyte Biotechnologies and Pharma15 and Enspire Bio.
